0001209191-19-058163.txt : 20191126 0001209191-19-058163.hdr.sgml : 20191126 20191126174326 ACCESSION NUMBER: 0001209191-19-058163 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191122 FILED AS OF DATE: 20191126 DATE AS OF CHANGE: 20191126 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Currie Mark G CENTRAL INDEX KEY: 0001478244 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38787 FILM NUMBER: 191252377 MAIL ADDRESS: STREET 1: C/O CYCLERION THERAPEUTICS, INC. STREET 2: 301 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cyclerion Therapeutics, Inc. CENTRAL INDEX KEY: 0001755237 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831895370 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 301 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-621-7722 MAIL ADDRESS: STREET 1: 301 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-11-22 0 0001755237 Cyclerion Therapeutics, Inc. CYCN 0001478244 Currie Mark G C/O CYCLERION THERAPEUTICS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142 0 1 0 0 President Employee Stock Option (Right to Buy) 2.01 2019-11-22 4 A 0 75000 0.00 A 2029-11-22 Common Stock 75000 75000 D The stock option grant will vest and become exercisable upon the attainment of both performance-based and service-based hurdles, as follows: (i) 20% of the shares subject to the option, if the average closing price of the common stock reported by Nasdaq for any thirty (30) consecutive trading days equals or exceeds $10; plus an additional (ii) 40% of the shares, if the average closing price equals or exceeds $20; plus an additional (iii) 40% of the shares, if the average closing price equals or exceeds $30; in each case, subject to the continuous employment or service through the later of the date that the performance hurdles set forth above are attained (but no later than December 31, 2024) and December 31, 2021. To the extent unvested as of December 31, 2024, all unvested shares underlying such performance-based option will be cancelled. /s/ David Slatcher, Attorney-in-Fact 2019-11-26